Presenter Information

Wesley Hood, University of Wyoming

Department

Department of Chemical and Petroleum Engineering

First Advisor

Dr. John Oakey

Second Advisor

Dr. David Bell

Description

At present, the food and drug administration (FDA) has not approved any fully implantable continuous glucose monitors (CGMs). Currently, diabetes patients cannot adjust the insulin dose their body needs solely based on readings made from CGMs. The FDA has only approved the use of CGMs as supplements, not replacements, to home blood glucose meters that require a small blood sample from a finger prick. Current CGMs that are in the market today have sensors that have to be replaced every three to seven days depending on the manufacturer. This has increased the work load associated with maintaining glucose levels as close to normal as possible. My senior design project aims to reduce the amount of work required by the patient and implement a fully closed-loop system to allow for insulin delivery without patient assistance. The product I designed is a closed-loop interstitial fluid (ISF) CGM. The glucose sensor will be placed in the ISF and will have a lifetime of a year or greater. Patients’ smartphones will be the computer receiving the reading from the glucose sensor. This reading along with patient inputs will allow the computer to decide the proper amount of insulin needing to be delivered and send that to the insulin delivery system. The insulin deliver system will then deliver the proper amount of insulin without patient assistance. These three separate devices will be connected through Bluetooth. My product will make the lives of diabetic patients much easier and has the possibility of making their expenses considerably less.

Comments

Oral Presentation

Share

COinS
 

Closed-Loop Interstitial Fluid Sensing Continuous Glucose Monitor

At present, the food and drug administration (FDA) has not approved any fully implantable continuous glucose monitors (CGMs). Currently, diabetes patients cannot adjust the insulin dose their body needs solely based on readings made from CGMs. The FDA has only approved the use of CGMs as supplements, not replacements, to home blood glucose meters that require a small blood sample from a finger prick. Current CGMs that are in the market today have sensors that have to be replaced every three to seven days depending on the manufacturer. This has increased the work load associated with maintaining glucose levels as close to normal as possible. My senior design project aims to reduce the amount of work required by the patient and implement a fully closed-loop system to allow for insulin delivery without patient assistance. The product I designed is a closed-loop interstitial fluid (ISF) CGM. The glucose sensor will be placed in the ISF and will have a lifetime of a year or greater. Patients’ smartphones will be the computer receiving the reading from the glucose sensor. This reading along with patient inputs will allow the computer to decide the proper amount of insulin needing to be delivered and send that to the insulin delivery system. The insulin deliver system will then deliver the proper amount of insulin without patient assistance. These three separate devices will be connected through Bluetooth. My product will make the lives of diabetic patients much easier and has the possibility of making their expenses considerably less.